School of Medicine
Showing 31-40 of 525 Results
-
Gill Bejerano
Professor of Developmental Biology, of Computer Science and of Pediatrics (Genetics)
Current Research and Scholarly Interests1. Automating monogenic patient diagnosis.
2. The genomic signatures of independent divergent and convergent trait evolution in mammals.
3. The logic of human gene regulation.
4. The reasons for sequence ultraconservation.
5. Cryptogenomics to bridge medical silos.
6. Cryptogenetics to debate social injustice.
7. Managing patient risk using machine learning.
8. Understanding the flow of money in the US healthcare system. -
Sean Bendall
Associate Professor of Pathology
Current Research and Scholarly InterestsOur goal is to understand the mechanisms regulating the development of human systems. Drawing on both pluripotent stem cell biology, hematopoiesis, and immunology, combined with novel high-content single-cell analysis (CyTOF – Mass Cytometry) and imagining (MIBI-Multiplexed Ion Beam Imaging) we are creating templates of ‘normal’ human cellular behavior to both discover novel regulatory events and cell populations as well as understand dysfunctional processes such as cancer.
-
Catherine Benedict, PhD
Clinical Associate Professor, Psychiatry and Behavioral Sciences - Medical Psychiatry
Current Research and Scholarly InterestsMy research focuses on improving cancer survivorship through better understanding of long-term health outcomes and through the development of theoretically driven, evidence-based behavioral interventions to improve adjustment, risk management, and quality of life. To this end, I lead studies aimed to guide and support patient decision-making and self-management after cancer. Much of my work focuses on the experiences of young adults affected by cancer.
-
Jonathan S. Berek, MD, MMSc
Laurie Kraus Lacob Professor
BioLaurie Kraus Lacob Professor
Stanford University School of Medicine
Founding Director, Stanford Women’s Cancer Center
Senior Advisor, Stanford Cancer Institute
Co-Chair, Senior Academy at Stanford Medicine
President, Stanford University Phi Beta Kappa
Director, MedArts Films
Faculty Director, Health Communication
Stanford Center for Health Education
A Stanford faculty member since 2005, Professor Berek is renowned for his many contributions to and expertise in gynecologic oncology, especially surgical innovation and techniques, and his research in immunology and immunotherapy. Through many laboratory and clinical investigations, he pioneered the use of regionally-administered immunotherapy in ovarian cancer patients. His early laboratory research focused on fundamental mechanisms of cancer immunology, elucidating growth regulatory pathways for cytokines and their receptors. His current research focuses on clinical trials of novel therapies and immunotherapies for ovarian cancer and collaborations on new diagnostics, screening techniques, and genetics.
An author and editor, Professor Berek has published more than 360 peer-reviewed manuscripts in the scientific literature, and numerous book chapters and monographs. His books, Berek & Hacker’s Gynecologic Oncology, now in its 7th edition, and Berek & Novak’s Gynecology, in its 17th edition, are leading texts in the field. He is the Series Editor for Operative Techniques in Gynecologic Surgery, for which five textbooks on various subspecialty topics in Obstetrics and Gynecology have been published. He serves as the Editor-in-Chief for Current Opinion in Obstetrics & Gynecology, and he is a former Editor-in-Chief of ASCO Connection, published by the American Society of Clinical Oncology.
Professor Berek received his Bachelor of Arts degree in English Literature and Theatre Arts, and a Master of Medical Sciences degree in biomedical sciences from Brown University. After earning his Doctor of Medicine from Johns Hopkins University School of Medicine, he completed an internship and residency at Harvard Medical School, Brigham & Women’s Hospital. Before moving to Stanford, he was on the faculty at the UCLA School of Medicine for more than two decades.
Professor Berek has received many honors and accolades. Dr. Berek is the 2019 Lifetime Achievement Honoree of the American Cancer Society for his many accomplishments in women’s cancer treatment and research. In 2022, he received a Lifetime Achievement Award from the International Society of Gynecologic Cancer for his contributions to the field of gynecologic oncology.
In addition to his medical career, Professor Berek is an active documentary filmmaker—creating and directing films on a variety of medical topics that are highlighted by patient stories. He is the Director and Producer of MedArts Films https://vimeo.com/medarts/videos. He directed a series of films for the Stanford Office of Medical Development, and many short films for the Stanford Center for Health Education that are found on YouTube at the Stanford Medicine Health Shelf. https://www.youtube.com/@Stanford_CHE/playlists
In collaboration with the Under One Umbrella Committee and Stanford Medical Center Development, Professor Berek has led a highly successful fundraising program for the Stanford Women’s Cancer Center. Since 2009, these Under One Umbrella philanthropy efforts have generated substantial support for innovative research programs in women’s cancer via concerts headlined by celebrities, including Nicole Kidman, Keith Urban, Trisha Yearwood, Garth Brooks, Tom Hanks, Rita Wilson, Carrie Underwood, Sheryl Crow, Vince Gill, Amy Grant, Darlene Love, and Harry Connick Jr.
https://www.facebook.com/StanfordWomensCancerCenter/ -
Dominique Bergmann
Shirley R. and Leonard W. Ely, Jr. Professor of the School of Humanities and Sciences
Current Research and Scholarly InterestsWe use genetic, genomic and cell biological approaches to study cell fate acquisition, focusing on cases where cell fate is correlated with asymmetric cell division.
-
Daniel Bernstein
Alfred Woodley Salter and Mabel G. Salter Endowed Professor of Pediatrics
Current Research and Scholarly Interests1. Using iPSC-derived cardiomyocytes to understand hypertrophic cardiomyopathy and heart failure associated with congenital heart disease.
2. Role of alterations in mitochondrial dycamics and function in normal physiology and disease.
3. Differences between R and L ventricular responses to stress,
4. Immune biomarkers of risk after pediatric VAD implantation.
5. Biomarkers for post-transplant lymphoproliferative disorder. -
Alice Bertaina MD, PhD
Lorry I. Lokey Professor
Current Research and Scholarly InterestsDr. Bertaina is a highly experienced clinician and will play a key role in supporting Section Chief Dr. Rajni Agarwal and Clinical Staff in the Stem Cell Transplant Unit at Lucile Packard Children’s Hospital. She will also continue her research on immune recovery and miRNA, understanding the mechanisms underlying immune reconstitution, Graft-versus-Host Disease (GvHD), and leukemia relapse after allogeneic HSCT in pediatric patients affected by hematological malignant and non-malignant disorders.
-
Carolyn Bertozzi
Baker Family Director of Sarafan ChEM-H, Anne T. and Robert M. Bass Professor in the School of Humanities and Sciences and Professor, by courtesy, of Chemical and Systems Biology
BioCarolyn Bertozzi is the Baker Family Director of Sarafan ChEM-H, Anne T. and Robert M. Bass Professor in the School of Humanities and Sciences and Professor, by courtesy, of Chemical and Systems Biology and of Radiology at Stanford University, and an Investigator of the Howard Hughes Medical Institute. She completed her undergraduate degree in Chemistry from Harvard University in 1988 and her Ph.D. in Chemistry from UC Berkeley in 1993. After completing postdoctoral work at UCSF in the field of cellular immunology, she joined the UC Berkeley faculty in 1996. In June 2015, she joined the faculty at Stanford University and became the co-director and Institute Scholar at Sarafan ChEM-H.
Prof. Bertozzi's research focuses on fundamental studies of disease-associated glycobiology and the development of new therapeutic modalities that target these pathways. Her inventions include bioorthogonal chemistries for in vivo imaging and bioconjugation, work for which she received the 2022 Nobel Prize in Chemistry. As well, her lab has developed next generation antibody-drug conjugates, lysosome-targeting chimeras (LYTACs), antibody-enzyme conjugates and antibody-lectin chimeras. Several of these new therapeutic modalities have been translated into clinical candidates for treatment of cancer and autoimmune diseases.
In addition to the Nobel Prize, Prof. Bertozzi has been recognized with many honors and awards for both her research and teaching accomplishments. For example, she is an elected member of the National Academy of Sciences, the National Academy of Medicine, the National Inventors Academy and the National Academy of Engineering, the American Academy of Arts and Sciences, the German Academy of Sciences Leopoldina, and she is a Foreign Fellow of the Royal Society. In addition, Prof. Bertozzi received the Priestley Medal of the American Chemical Society, the Welch Award, the Wolf Prize in Chemistry, the Heineken Prize, Lemelson-MIT award for inventors, and a MacArthur "Genius Award". -
Allison Betof, MD, PhD, FASCO
Associate Professor of Medicine (Oncology)
BioDr. Allison Betof is an Associate Professor of Medicine (Oncology), Director of the Melanoma Program, Director of Solid Tumor Cellular Therapy, and Mark & Mary Stevens Endowed Scholar in Melanoma at Stanford University School of Medicine. Dr. Betof completed her MD and PhD at Duke University, Internal Medicine residency at Massachusetts General Hospital (Harvard University) and Medical Oncology Fellowship at Memorial Sloan Kettering Cancer Center. Dr. Betof’s laboratory focuses on understanding resistance to immune checkpoint blockade and cellular therapies for melanoma and other solid tumors. She is the Principal Investigator of clinical trials exploring novel treatments for immunotherapy-refractory melanoma and is internationally recognized for her expertise in brain/CNS metastasis and the use of novel cellular therapies. Dr. Betof has been a pioneer in the use of commercial tumor infiltrating lymphocyte (TIL) therapy for the treatment of melanoma and other solid tumors. She has received funding and awards for her clinical and translational investigative work from multiple high-profile organizations, including the American Society of Clinical Oncology (ASCO), National Institutes of Health (NIH), Melanoma Research Alliance, and Melanoma Research Foundation.
-
Ami Bhatt
Professor of Medicine (Hematology) and of Genetics
Current Research and Scholarly InterestsThe Bhatt lab is exploring how the microbiota is intertwined with states of health and disease. We apply the most modern genetic tools in an effort to deconvolute the mechanism of human diseases.